Antiretroviral Protease Inhibitors Market

Segmentation By Mechanism of Action (Serine Protease Inhibitors, Cysteine Protease Inhibitors, Amino Peptidase Inhibitor, Aspartic Protease Inhibitors, Metallo-Protease Inhibitors, and Others); By Disease Indication (HIV/AIDS, Hepatitis C and Others); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies) and By End User - Global Demand Analysis & Opportunity Outlook 2028

Buy Now
Report ID: 2553 | Published On: Feb 07, 2023
Request Free Sample Copy

Growth Driver

Increasing Appeal of Protease Inhibitor to Boost Market Growth

Protease inhibitors are being used in various fields now-a-days. They are used in research for clinical application, drugs for treatment of diseases such as HIV/AIDS and Hepatitis C and others. On the back of this increasing product appeal antiretroviral protease inhibitors are anticipated to fuel the market growth in the forecast period.

High Prevalence of HIV and HCV to Drive Market Growth

Antiretroviral protease inhibitors are major drugs in the treatment of diseases such as HIV and HCV. With the increasing number of cases coupled with high prevalence of these diseases the demand for these drugs are bound to increase as well. Thereby, it is anticipated that the market for antiretroviral protease inhibitor will show significant CAGR over the forecast period.


Side Effects of Drugs to Hamper Growth

Antiretroviral protease inhibitors have side effects and unbearable toxicity and hence people hesitate in using these drugs. So there is a challenge in-front of drug manufacturing companies to innovate and prepare drug which have either no side effects or they have only a few non-severe side effects.

Stringent Regulation Environment to Hamper Market Growth

In an effort to protect public from harmful drug effects, governments make rule and regulations stringent. Usually government regulations make product development more expensive. Such environment can create a hindrance in the market growth in that region.

Time Consuming Approval Process of Drugs to Restrain Market Growth

From the time of research and development to the official launch of drugs, it takes a very long time. Even after development and successful trials, approval from regulatory authority takes a lot of time and a lot of entrepreneurs and big players do not invest in drug manufacturing due to this reason. Over the forecast period this may hamper the growth of injectable drug for type 2 diabetes market.

Get more information on this report: Request Sample PDF

Market Size and Forecast

Global antiretroviral protease inhibitors market is anticipated to record a significant CAGR over the forecast period, i.e., 2020-2028. The primary factor for the growth of the market can be attributed to increasing prevalence of diseases such as HIV and HCV. Extensive research and development activities in the field of HIV treatment using protease inhibitors coupled with the rising awareness of antiretroviral therapy is expected to boost the market growth.

The market is further segmented by mechanism of action, disease indication, distribution channel, end user, and region. On the basis of mechanism of action, market is further sub-segmented into serine protease inhibitors, cysteine protease inhibitors, amino peptidase inhibitor, aspartic protease inhibitors, metallo-protease inhibitors, and others. Serine protease inhibitor segment leads the market and it is anticipated to drive the growth for antiretroviral drugs in the market on the back of its effectiveness in the treatment.

The high prevalence of diseases such as HIV and HCV has increased the demand for drugs in hospitals and diagnostic centres. Moreover, with the increasing popularity of online pharmacies the supply chain in the field of drug delivery is expected to improve tremendously. On the back of these factors the global antiretroviral protease inhibitor market is expected to grow notably over the forecast period. 

Market Segmentation

Our in-depth analysis of the global antiretroviral protease inhibitors market includes the following segments:

By Mechanism of Action

  • Serine Protease Inhibitors
  • Cysteine Protease Inhibitors
  • Amino Peptidase Inhibitor
  • Aspartic Protease Inhibitors
  • Metallo-Protease Inhibitors
  • Others

By Disease Indication

  • Hepatitis C
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By End User

  • Hospitals & Diagnostic Centres
  • Pharmaceutical Industries
  • Academic & Research Institutes

By Region

On the basis of regional analysis, the global antiretroviral protease inhibitors market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region.

North American region is anticipated to dominate the global protease inhibitors market, during the forecast period owing to increasing cases of HIV and chronic HCV, growing industrial sector, and advanced health care infrastructure in the region. Asia Pacific region is expected to register the maximum CAGR during the forecast period, owing to factors such as rising health care expenditure and increasing focus of global pharmaceutical companies on Asia Pacific region. Rise in awareness about the antiretroviral diseases in the Asian and African region will drive the growth of the market.

The antiretroviral protease inhibitors market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
  • Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis.
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis

Get more information on this report: Request Sample PDF

Top Featured Companies Dominating the Market

    • Janssen Pharmaceuticals Company Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Boehringer Ingelheim Pharmaceuticals, Inc.
    • Thermo Fisher Scientific Inc.
    • Sigma-Aldrich, Inc.
    • Merck & Co., Inc.
    • Genentech, Inc.
    • AbbVie Inc.
    • Tibotec Pharmaceuticals
    • Bristol-Myers Squibb Company

In The News

  • April 2020 — San Diego Supercomputer Center (SDSC) researchers reported that they have created a pharmacophore model and conducted data mining of the conformational database of FDA-approved drugs. These drugs are known to identify 64 compounds as potential inhibitors of the COVID-19 protease.

  • July 2018 - Janssen Pharmaceuticals Company announced that it has received the FDA approval for its protease inhibitor class of drug, known as SYMTUZA, which is anticipated to be used for the treatment of HIV infection.

Global Economic Impact

Request Insights
Despite Inflation & Fearing Recession, Businesses Across the Globe Expected to Do Better in 2023:

In 2023, market players might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain.
Controlling Inflation has become the first priority for global economies from last quarter of 2022 and to be followed in 2023. With skewed economic situations, rise in interest rate by governments to control spending and inflation, spiked oil and gas prices, high inflation, geo-political issues including U.S. & China trade war, Russia-Ukraine conflict to intensify the global economic issues.
The interest rates in the U.S. may be less sensitive in 2023 as compared to 2022; sigh of relief for businesses. Positive business sentiments, healthy business balance sheets, growth in construction spending (private construction value in 2022 stood at $1,429.2 billion, 11.7 percent (±1.0 percent) above the $1,279.5 billion spent in 2021, Residential construction in 2022 was $899.1 billion, up by 13.3 percent (±2.1 percent) from $793.7 billion in 2021, non-residential construction touched $530.1 billion, 9.1 percent (±1.0 percent) above the $485.8 billion in 2021.) showcases minimal impact of recession in the country.
Similarly, spiked spending in the European and major Asia economics including, India, China & Japan to showcase less impact on the global demand.

Let Us Hear About Your Requirements:

Submit Your Request For Proposal (RFP)

Request Research Report Sample